The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study-Reference-Cited by-同舟云学术

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

Published:2014-01 Issue:1 Volume:24 Page:43-51
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

de Keyser Catherine E.,Peters Bas J.M.,Becker Matthijs L.,Visser Loes E.,Uitterlinden André G.,Klungel Olaf H.,Verstuyft Céline,Hofman Albert,Maitland-van der Zee Anke-Hilse,Stricker Bruno H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference24 articles.

1. The discovery and development of HMG-CoA reductase inhibitors.;Endo;J Lipid Res,1992

2. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.;Neuvonen;Clin Pharmacol Ther,2006

3. Statin-associated myopathy.;Thompson;JAMA,2003

4. Pharmacogenomics of statin response.;Mangravite;Curr Opin Lipidol,2007

5. Pharmacogenomics of statin response.;Mangravite;Curr Opin Mol Ther,2008

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of OATP Variants on the Side Effects of Direct-Acting Antivirals in Hepatitis C Patients;2024-07-01

2. Publication bias in pharmacogenetics of statin-associated muscle symptoms, an umbrella review with a meta-epidemiological study;2024-03-08

3. Cardiovascular pharmacogenomics – Molecular basis of protective and adverse drug response;Genomic and Molecular Cardiovascular Medicine;2024

4. Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users;Genes;2023-02-10

5. Cardiovascular precision medicine – A pharmacogenomic perspective;Cambridge Prisms: Precision Medicine;2023